Clinical trials: APC Gene Mutation
Colorectal Cancer, APC Gene Mutation
Patogenic Mutation in 5 Genes
This is a pathogenic mutation profile of colorectal patients specifically in 5 genes, i.e. APC, TP53, PIK3CA, KRAS, and MLH1. Single nucleotide variants identified were synchronized with patients' characteristics.
- Conditions
- Colorectal Cancer, APC Gene Mutation, TP53 Gene Mutation, PIK3CA Gene Mutation
- Trial name
- NCT04976439
- Testing
- co-occuring mutation
- Where
- Indonesia
- Volunteers
- 22 people
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
BRCA1 Mutation, POLD1 Gene Mutation
An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results
The purpose of this study is to examine the impact of new cancer genetic counseling models that aim to increase patient engagement with the genetics team.
- Conditions
- BRCA1 Mutation, POLD1 Gene Mutation, CDKN2A Mutation, BRCA2 Mutation
- Trial name
- NCT05420064
- Testing
- Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care
- Where
- 8 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Li Fraumeni Syndrome, Lynch Syndrome
Inherited Cancer Early Diagnosis (ICED) Study
ICED is a prospective sample collection research study, aiming to develop or validate a blood/urine biomarker which could potentially detect cancers early in individuals at high risk of developing cancers, due to certain germline…
- Conditions
- Li Fraumeni Syndrome, Lynch Syndrome, Hereditary Diffuse Gastric Cancer, Cowden Syndrome
- Trial name
- ICED (NCT06163365)
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.
FAP-Familial Adenomatous Polyposis
Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis
Colorectal cancer (CRC) is a leading cause for cancer related mortality in the western world with a lifetime risk of 6%. Etiology is complex, while genetic background significantly affects the risk.
- Trial name
- NCT02175914
- Testing
- Erythromycin
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- michal roll
Familial Adenomatous Polyposis
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
This is a multicenter, two-part trial in participants with FAP.
- Trial name
- TUPELO (NCT05552755)
- Testing
- REC-4881
- Where
- 17 sites in United States
- Volunteers
- 67 people
- Sponsor
- Recursion Pharmaceuticals Inc.
Quality of Life
French Digestive Polyposis Cohorte Family Adenomatous Polyposis With APC and MYH Gene Mutations , Cowden's Disease With PTEN Gene Mutation, Peutz Jeghers Disease With STK 11 Gene Mutation ,juvénil Polyposis With SMAD 4 Gene Mutation , Serrated and Hyperplastic Polyposis
French cohorte about polyposis digestive diseases
- Trial name
- NCT01987518
- Testing
- Procedure surgery behavioral and genetic diagnosis, quality of life after different type of surgery
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Hôpital Edouard Herriot
Familial Adenomatous Polyposis
Azithromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis
Colorectal cancer (CRC) is a leading cause for cancer related mortality in the western world with a lifetime risk of 6%. Etiology is complex, while genetic background significantly affects the risk.
- Trial name
- FAP (NCT04454151)
- Testing
- Azithromycin Tablets
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Covid19
Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients with controlled cancers. 1.
- Trial name
- COVSP-BCG (NCT03305341)
- Testing
- COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Globus Sensations in the Throat
Long Term Outcome of Argon Plasma Coagulation of Cervical Heterotopic Gastric Mucosa as an Alternative Treatment for Globus Sensations
APC of gastric inlet patches is successful for the treatment of globus sensations in the throat (Bajbouj et al Gastroenterology 2009; 137:440-4). There is no data for long term efficiency of this treatment.
- Trial name
- ACHAT FU (NCT01574755)
- Volunteers
- 49 people
- Sponsor
- Technical University of Munich
Gardner Syndrome, Colorectal Carcinoma
A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome
The purpose of this study is to assess the long-term outcome in a cohort of Gardner-Syndrome patients receiving prophylaxis and treatment for intestinal and non-intestinal tumors.
- Conditions
- Gardner Syndrome, Colorectal Carcinoma, Desmoid Tumor
- Trial name
- NCT01286662
- Volunteers
- 105 people
- Sponsor
- Triemli Hospital
Duodenum Cancer, Familial Adenomatous Polyposis
Duodenal Polyposis Classification in FAP
Duodenal cancer is the leading cause of cancer-related mortality in patients with familial adenomatous polyposis (FAP), yet the current Spigelman staging system provides limited predictive accuracy for advanced neoplasia.
- Conditions
- Duodenum Cancer, Familial Adenomatous Polyposis, Duodenal Polyposis, Ampulla of Vater Adenoma
- Trial name
- DRACO (NCT07199127)
- Testing
- DRACO
- Where
- 2 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
AXIN1 Gene Mutation, APC Gene Mutation
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors…
- Conditions
- AXIN1 Gene Mutation, APC Gene Mutation, Solid Tumor
- Trial name
- NCT06005974
- Testing
- REC-4881
- Where
- 13 sites in United States
- Volunteers
- 18 people
- Sponsor
- Recursion Pharmaceuticals Inc.
Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC)
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
This trial will evaluate the safety, tolerability, and preliminary efficacy of tegavivint as monotherapy (single) and in combination with standard therapies in patients with metastatic colorectal carcinoma (mCRC).
- Conditions
- Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC), Adenomatous Polyposis Coli (APC) Gene Mutation, Catenin Beta-1 (CTNNB1) Gene Mutation
- Trial name
- NCT07463599
- Testing
- Tegavivint
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- HonorHealth Research Institute
FAP-Familial Adenomatous Polyposis
Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version
Colorectal cancer (CRC) is a leading cause for cancer related mortality in the western world with a lifetime risk of 6%. Etiology is complex, while genetic background significantly affects the risk.
- Trial name
- NCT02354560
- Testing
- Erythromycin
- Volunteers
- 15 people
- Sponsor
- michal roll
Familial Adenomatous Polyposis, FAP
Turmeric Supplementation on Polyp Number and Size in Patients With Familial Adenomatous Polyposis.
A Phase 2, randomized, double blind, placebo controlled trial for the effectivness of wholistic turmeric supplementation on polyp burden mong patients with Familial Adenomatouse Polyposis (FAP).
- Conditions
- Familial Adenomatous Polyposis, FAP, FAP Gene Mutation
- Trial name
- NCT03061591
- Testing
- Wholistic Turmeric capsules
- Volunteers
- 40 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
MutYH-associated Polyposis
MUTYH-associated Polyposis
This is single-center, prospective, non-randomized study
- Trial name
- MAP (NCT03847532)
- Testing
- Sanger sequencing method
- Where
- Russia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- State Scientific Centre of Coloproctology, Russian Federation